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On behalf of: on behalf of ESC-HF-LT registry investigators 
Introduction: Intravenous (IV) inotropes and vasopressors are widely used in the initial treatment 
of acute heart failure (AHF). There is a continuing controversy about whether one agent is superior 
to the other. Our aim was to analyze current real-life use of inotropes and/or vasopressors, and 
their association with all-cause long-term mortalityin a large AHF cohort. 
 
Methods: The European Society of Cardiology Heart Failure Long – Term Registry (ESC-HF-LT) 
was conducted between 2011 and 2013 and included 12785 patients (pts) in 21 countries in 
Europe, Northern Africa and the Middle East. Median duration of follow-up was 381 [363; 457] 
days. 833 (6.5%) AHF pts who received IV inotropes and/or vasopressors were identified for the 
post-hoc analysis. Propensity score for inotrope and/or vasopressor treatment was estimated using 
35 clinically relevant baseline variables. Matching was made 1:1 on inotropic medication versus 
no inotropic medication and derived 606 pts in each treatment group. Hazard ratio (HR) for all-
cause long-term mortality was estimated.  
 
Results: Mean age of pts was 67 (± 13) years and 33.4% were women. Mean systolic blood 
pressure at presentation was 112 (± 27) mmHg. 45.7% of pts treated with inotropes had signs of 
hypoperfusion and 19.0% presented with cardiogenic shock. The 3 most widely used inotropes 
were dobutamine (42.5%), dopamine (24.7%) and levosimendan (13.1%), although their use 
varied among different regions (table 1). Median duration of treatment was 36.0 hours (h) [23.0; 
72.0] for dobutamine, 36.0h [20.0; 72.0] for dopamine and 24.0h [24.0; 24.0] for levosimendan. 
Adjusted HR confirmed a significant association between the use of dopamine and all-cause long-
term mortality (1.628 [1.031-2.572]) in the matched cohort. By contrast, no such association was 
seen with patients receiving dobutamine or levosimendan (HR 1.055 [0.727-1.531] and 1.229 
[0.618-2.445] respectively).  
 
Conclusions: Most commonly used inotropes in AHF patient population were dobutamine, 
dopamine and levosimendan. Compared to other inotropes, the use of dopamine was associated 
with markedly higher all-cause long-term mortality.  
  
Inotropes in different regions 
IV inotrope  
Eastern Europe 
(n=303) 
North Africa and 
Middle East (n=148) 
Northern and 
Western Europe 
(n=90) 
Southern Europe 
(n=292) 
All 
(n=833) 
      
Dobutamine  40.6%  61.5%  53.3%  31.5%  42.5% 
Dopamine  30.4%  23.6%  10.0%  24.0%  24.7% 
Levosimendan  6.6%  0.0%  22.2%  23.6%  13.1% 
Other  22.4%  14.9%  14.4%  20.9%  19.7% 
      
 
 
